1: Bassetti M, Castaldo N, Fantin A, Giacobbe DR, Vena A. Antibiotic therapy for nonfermenting Gram-negative bacilli infections: future perspectives. Curr Opin Infect Dis. 2023 Dec 1;36(6):615-622. doi: 10.1097/QCO.0000000000000984. Epub 2023 Oct 16. 67(7):e0033923. doi: 10.1128/aac.00339-23. Epub 2023 May 31.
3: Karvouniaris M, Almyroudi MP, Abdul-Aziz MH, Blot S, Paramythiotou E, Tsigou E, Koulenti D. Novel Antimicrobial Agents for Gram-Negative Pathogens. Antibiotics (Basel). 2023 Apr 16;12(4):761. doi: 10.3390/antibiotics12040761.
4: Hung KC, Tsai WW, Hsu CW, Lai CC, Tang HJ, Chen IW. Clinical efficacy and safety of novel antibiotics for complicated urinary tract infection: A systematic review and meta-analysis of randomized controlled trials. Int J Antimicrob Agents. 2023 Jul;62(1):106830. doi: 10.1016/j.ijantimicag.2023.106830. Epub 2023 Apr 24. 66(6):3866-3875. doi: 10.1021/acs.jmedchem.2c01025. Epub 2023 Mar 14.

合成参考文献

摘要:Kleemann A., Kutscher B., Reichert D., Bossart M., Pharmaceutical Substances, Thieme [Online], Stuttgart, (2025).
参考文献:10.1128/aac.00180-20|10.1128/aac.01076-20
摘要:Das S, Johnson A, McEntee L, Farrington N, Kirby A, Unsworth J, Jimenez-Valverde A, Kolamunnage-Dona R, Bousquet J, Alibaud L, Sable C, Zalacain M, Everett M, Hope W. Pharmacodynamics of the Novel Metallo-β-Lactamase Inhibitor ANT2681 in Combination with Meropenem for the Treatment of Infections Caused by NDM-Producing Enterobacteriaceae. Antimicrob Agents Chemother. 2020 Oct 20;64(11).
参考文献:10.1016/j.ijantimicag.2020.105925
摘要:Tselepis L, Langley GW, Aboklaish AF, Widlake E, Jackson DE, Walsh TR, Schofield CJ, Brem J, Tyrrell JM. In vitro efficacy of imipenem-relebactam and cefepime-AAI101 against a global collection of ESBL-positive and carbapenemase-producing Enterobacteriaceae. International Journal of Antimicrobial Agents. 2020 Jul;56(1):105925. doi: 10.1016/j.ijantimicag.2020.105925.